Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Lucid is planning on bringing #CheckYourFoodTube events to more ex-NFL stars in cities across the U.S., with a goal of ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...

After a relatively quiet stretch, Aspen Neuroscience is rolling out a major upgrade to its in-house manufacturing. | Aspen is ...

Roughly a year and a half after the introduction of a damning shareholder lawsuit, Amgen has lost its bid to toss the case ...

Looking back over Verrica's second-quarter financial results released in August, it's easy to spot the problem. Selling, ...

Under the new cooperation deal, Recipharm gets access to Exela’s manufacturing plant in Lenoir, North Carolina. Exela is ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

On the same day that Johnson & Johnson confirmed layoffs at its home base in New Jersey | Officials in Wilson, North Carolina ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...